Integra LifeSciences Holding Corporation, a world leader in medical technology, announced that its CUSA Excel+ system is the first and only ultrasonic tissue ablation system cleared by the FDA for liver resection and tumour removal.
Previously cleared for a wide variety of surgical applications, this new, specific indication demonstrates both Integra's continued leadership in ultrasonic tissue ablation and its focus on safety and optimisation in the operating room.
The CUSA Excel+ system improves efficiency in liver surgery for both laparoscopic and open surgical procedures, including the removal of benign or malignant tumours or other unwanted tissue, liver transplantation, living donor transplantation and paediatric liver surgery. Its proprietary technology promotes safety without sacrificing speed by helping the surgeon to maintain the integrity of critical blood vessels. The CUSA Excel+ system can help with lessening blood loss during liver procedures and might reduce the need for intraoperative blood transfusion. Additional benefits to the patient may include reduced length of procedure and reduced hospital stay.
"We are very excited to receive this new liver indication for our CUSA Excel+ system," said Bob Davis, Integra's corporate vice president, and president - Specialty Surgical Solutions.
"This expanded indication represents another example of our commitment to offer surgeons safe and effective products that help them achieve the best outcome for their patients."
Since 1977, the CUSA name has been associated with premium quality and innovation in ultrasonic ablation. CUSA systems have led the ultrasonic tissue ablation market for over 30 years, and are recognized worldwide for optimizing removal of fibrous and soft tissue.